Apogee Therapeutics, Inc.
NASDAQ:APGEBiotechnology
+$1.05 today
- Market cap
- $8.36B
- Beta
- 0.62
- P/E (TTM)
- -22.7
- EPS (TTM)
- -$3.94
Volume 0.00M
Average 0.97M
APGE Total Debt
Short-term and long-term borrowings combined.
Apogee Therapeutics, Inc.NASDAQ: APGE
Total Debt · Q2 FY2026 · quarter ended Jun 2026
Total debt falls 37.0% from a year ago
Total debt stood at $6.83M at the end of Q2 FY2026, down 37.0% from a year earlier and down 15.1% from the prior quarter.
Context
- Total debt amounted to 0.5% of total assets at the end of Q2 FY2026, down 1.1 pp from a year earlier.
- Total debt increased in 2 of the last 3 fiscal years.
What to watch
Whether total debt keeps falling in the next quarterly balance sheet after a -37.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Debt history
USD · from the balance sheet
- Latest · FY2025
- 8.85M USD
- Year-over-year change
- -25.2%
| Period | Period end | Total Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 8.85M | -25.2% |
| FY2024 | 2024-12-31 | 11.83M | +481.7% |
| FY2023 | 2023-12-31 | 2.03M | — |
| FY2022 | 2022-12-31 | 0 | — |
Total Debt vs competitors
How APGE compares with its peers on the latest reported figures
- Peers report in different currencies, so total debt is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -37.0% is the 8th highest of 10, against a peer median of +27.6%.
- Total debt amounts to 0.5% of total assets for APGE, versus a peer median of 10.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
AAPGAscentage Pharma Group International | Dec 2025 | CN¥1.98B CNY | +18.7% | +3.4% | 49.9% |
| Mar 2026 | $1.2B USD | +3035.4% | +243.1% | 92.6% | |
| Jun 2026 | $754.39M USD | +658.8% | +77.0% | 91.1% | |
| Jun 2026 | $254.58M USD | +33.0% | +122.4% | 23.7% | |
| Sep 2026 | $167.4M USD | -59.2% | +13.3% | 10.0% | |
IRONDisc Medicine, Inc. | Sep 2026 | $61.09M USD | +97.2% | +11.8% | 8.7% |
| Sep 2026 | $9.24M USD | +27.6% | -23.9% | 0.9% | |
| Mar 2026 | $7.37M USD | -93.8% | -52.3% | 1.1% | |
| Jun 2026 | $6.83M USD | -37.0% | — | 0.5% | |
| Sep 2026 | $6.01M USD | -27.8% | -8.7% | 0.5% | |
| Peer median (excluding APGE) | — | +27.6% | +11.8% | 10.0% | |
Competitors are the stored peer set for APGE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Apogee Therapeutics, Inc.
NASDAQ:APGE
Intrinsic Alpha fair value
Locked
Current Price
$135.07
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.